-
摘要: 血脂异常是动脉粥样硬化的重要危险因素之一，但有患者接受传统降脂治疗不能达到满意的血脂控制。已有大量相关研究证实前蛋白转化酶枯草杆菌蛋白酶/kexin 9型(PCSK9)在脂质代谢中起到重要作用，因此PCSK9抑制剂近年受到了广泛关注。目前已有证据表明其在降脂应用的安全性与有效性。本文就PCSK9在脂质稳态中的作用，总结了目前PCSK9抑制剂的作用机制，针对PCSK9抑制剂在高脂血症、冠心病、糖尿病患者等特殊患者中的临床应用与进展进行综述，为其在临床应用中提供参考依据。Abstract: Dyslipidemia is one of the risk factors related to atherosclerosis. However, some patients received traditional lipid-lowering therapy did not achieve the target lipid reduction. The proprotein convertase subtilisin / kexin type 9(PCSK9) plays an important role in lipid metabolism. Therefore, PCSK9 inhibitors have received extensive attention in recent years. At present, a large number of studies have confirmed its lipid-lowering effect and the safety and effectiveness of application. The purpose of this article is to summarize the current mechanism of PCSK9 inhibitors and review the clinical application and progress of PCSK9 inhibitors in patients with hyperlipidemia, coronary heart disease, diabetes and other special patients, in order to provide reference for their clinical application.
-
Key words:
- PCSK9 inhibitors /
- coronary heart disease /
- lipid metabolism disorder
-
-
[1] Seidah NG. The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol[J]. Glob Cardiol Sci Pract, 2017, 2017(1): e201702.
[2] Puteri MU, Azmi NU, Kato M, et al. PCSK9 Promotes cardiovascular diseases: recent evidence about its association with platelet activation-induced myocardial infarction[J]. Life(Basel), 2022, 12(2): 112.
[3] Luquero A, Badimon L, Borrell-pages M. PCSK9 functions in atherosclerosis are not limited to plasmatic ldl-cholesterol regulation[J]. Front Cardiovasc Med, 2021, 8: 639727. doi: 10.3389/fcvm.2021.639727
[4] Warden BA, Duell PB. Inclisiran: a novel agent for lowering apolipoprotein B-containing lipoproteins[J]. J Cardiovasc Pharmacol, 2021, 78(2): e157-e74. doi: 10.1097/FJC.0000000000001053
[5] Gennemark P, Walter K, Clemmensen N, et al. An oral antisense oligonucleotide for PCSK9 inhibition[J]. Sci Transl Med, 2021, 13(593): 112.
[6] Seidah NG, Prat A, Pirillo A, et al. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies[J]. Cardiovasc Res, 2019, 115(3): 510-518. doi: 10.1093/cvr/cvz003
[7] Carreras A, Pane LS, Nitsch R, et al. In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse model[J]. BMC Biol, 2019, 17(1): 4. doi: 10.1186/s12915-018-0624-2
[8] Emmer BT, Hesketh GG, Kotnik E, et al. The cargo receptor SURF4 promotes the efficient cellular secretion of PCSK9[J]. Elife, 2018, 30: 7.
[9] Shen Y, Wang B, Deng S, et al. Surf4 regulates expression of proprotein convertase subtilisin/kexin type 9(PCSK9) but is not required for PCSK9 secretion in cultured human hepatocytes[J]. Biochim Biophys Acta Mol Cell Biol Lipids, 2020, 1865(2): 158555.
[10] Katzmann JL, Gouni-berthold I, Laufs U. PCSK9 inhibition: insights from clinical trials and future prospects[J]. Front Physiol, 2020, 11: 595819. doi: 10.3389/fphys.2020.595819
[11] Katzmann JL, Custodis F, Schirmer SH, et al. Update on PCSK9 inhibition[J]. Herz, 2022, 22: 120.
[12] Mitchell T, Chao G, Sitkoff D, et al. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering[J]. J Pharmacol Exp Ther, 2014, 350(2): 412-424. doi: 10.1124/jpet.114.214221
[13] Lu X. Structure and function of proprotein convertase subtilisin/kexin type 9(PCSK9) in hyperlipidemia and atherosclerosis[J]. Curr Drug Targets, 2019, 20(10): 1029-1040. doi: 10.2174/1389450120666190214141626
[14] Blom DJ, Harada-shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: The ODYSSEY HoFH Trial[J]. J Am Coll Cardiol, 2020, 76(2): 131-142. doi: 10.1016/j.jacc.2020.05.027
[15] Farnier M, Hovingh GK, Langslet G, et al. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program[J]. Atherosclerosis, 2018, 278: 307-314. doi: 10.1016/j.atherosclerosis.2018.08.036
[16] Santos RD, Stein EA, Hovingh GK, et al. Long-term evolocumab in patients with familial hypercholesterolemia[J]. J Am Coll Cardiol, 2020, 75(6): 565-574. doi: 10.1016/j.jacc.2019.12.020
[17] Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia[J]. J Am Coll Cardiol, 2019, 74(17): 2132-2146. doi: 10.1016/j.jacc.2019.08.1024
[18] 韩雅玲, 马颖艳, 苏国海, 等. 阿利西尤单抗与依折麦布治疗高胆固醇血症合并心血管高危患者的疗效及安全性比较: ODYSSEY EAST研究中国地区亚组分析[J]. 中华心血管病杂志, 2020, 48(7): 593-599. doi: 10.3760/cma.j.cn112148-20191216-00755
[19] Chao TH, Hsiao PJ, Liu ME, et al. A subanalysis of Taiwanese patients from ODYSSEY South Korea and Taiwan study evaluating the efficacy and safety of alirocumab[J]. J Chin Med Assoc, 2019, 82(4): 265-271. doi: 10.1097/JCMA.0000000000000062
[20] Stein EA, Somaratne R, Djedjos C, et al. PCSK9 inhibition-meditated reduction in triglyceride with Evolocumab is related to baseline triglyceride levels: An analysis from 1791 patients[J]. JACC, 2016, 67(13, Supplement): 1866. doi: 10.1016/S0735-1097(16)31867-8
[21] Peng Y, Guo D, Jiang S, et al. Application of proprotein convertase subtilisin/kexin type 9 inhibitor, evolocumab, in patients with severe hypertriglyceridemia[J]. Chin Med J(Engl), 2022, 135(6): 730-731.
[22] Sugizaki Y, Otake H, Kawamori H, et al. Adding alirocumab to rosuvastatin helps reduce the vulnerability of thin-cap fibroatheroma: An ALTAIR Trial Report[J]. JACC Cardiovasc Imaging, 2020, 13(6): 1452-1454. doi: 10.1016/j.jcmg.2020.01.021
[23] Gao F, Wang ZJ, Ma XT, et al. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography[J]. Lipids Health Dis, 2021, 20(1): 106. doi: 10.1186/s12944-021-01528-3
[24] Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes(EVOPACS)[J]. J Am Coll Cardiol, 2019, 74(20): 2452-2562. doi: 10.1016/j.jacc.2019.08.010
[25] White HD, Steg PG, Szarek M, et al. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial[J]. Eur Heart J, 2019, 40(33): 2801-2809. doi: 10.1093/eurheartj/ehz299
[26] Steg PG, Szarek M, Bhatt DL, et al. Effect of alirocumab on mortality after acute coronary syndromes[J]. Circulation, 2019, 140(2): 103-112. doi: 10.1161/CIRCULATIONAHA.118.038840
[27] Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI Randomized Clinical Trial[J]. JAMA, 2022, 327(18): 1771-1781. doi: 10.1001/jama.2022.5218
[28] Colhoun HM, Leiter LA, Müller-wieland D, et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol[J]. Cardiovasc Diabetol, 2020, 19(1): 14. doi: 10.1186/s12933-020-0991-1
[29] Leiter LA, Cariou B, Müller-wieland D, et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial[J]. Diabetes Obes Metab, 2017, 19(12): 1781-1792. doi: 10.1111/dom.13114
[30] Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2017, 5(12): 941-950. doi: 10.1016/S2213-8587(17)30313-3
[31] Colhoun HM, Leiter LA, Müller-wieland D, et al. Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol[J]. Cardiovasc Diabetol, 2020, 19(1): 14. doi: 10.1186/s12933-020-0991-1
[32] Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER Randomized Clinical Trial[J]. JAMA Cardiol, 2021, 6(2): 139-147. doi: 10.1001/jamacardio.2020.3151
[33] Ostadal P, Steg PG, Poulouin Y, et al. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial[J]. Lancet Diabetes Endocrinol, 2022, 10(5): 330-340. doi: 10.1016/S2213-8587(22)00043-2
[34] Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab in statin-intolerant patients over 3 years: open-label treatment period of the ODYSSEY ALTERNATIVE trial[J]. J Clin Lipidol, 2020, 14(1): 88-97.e2. doi: 10.1016/j.jacl.2020.01.001
[35] Nissen SE, Stroes E, Dent-acosta RE, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: The GAUSS-3 Randomized Clinical Trial[J]. Jama, 2016, 315(15): 1580-1590. doi: 10.1001/jama.2016.3608
[36] Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER Trial[J]. J Am Coll Cardiol, 2019, 73(23): 2961-2970. doi: 10.1016/j.jacc.2019.03.513
[37] Tuñón J, Steg PG, Bhatt DL, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial[J]. Eur Heart J, 2020, 41(42): 4114-4123. doi: 10.1093/eurheartj/ehaa498
[38] Singh M, Mcevoy JW, Khan SU, et al. Comparison of transatlantic approaches to lipid management: the AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines[J]. Mayo Clin Proc, 2020, 95(5): 998-1014. doi: 10.1016/j.mayocp.2020.01.011
[39] Hao Q, Aertgeerts B, Guyatt G, et al. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations[J]. Bmj, 2022, 377: e069066.
-
计量
- 文章访问数: 1449
- PDF下载数: 645
- 施引文献: 0
下载: